The Impact of mTOR Inhibitors on the Development of Malignancy

Transplantation Proceedings

Volumn 40, Issue 10 SUPPL., 2008, Pages

  Geissler, E K ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CELL PROLIFERATION; CELL SURVIVAL; DRUG SUBSTITUTION; GLIOBLASTOMA; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; KAPOSI SARCOMA; KIDNEY GRAFT REJECTION; LIVER CELL CARCINOMA; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SKIN CANCER; TRANSPLANTATION; VIRUS INFECTION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM RECURRENCE, LOCAL; PROTEIN KINASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS;

EID: 57649111326     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.10.017     Document Type: Article

References (23)

1. Webster A.C., Craig J.C., Simpson J.M., et al. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15 183 recipients. Am J Transplant 7 (2007) 2140
2. Grulich A.E., van Leeuwen M.T., Falster M.O., et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370 (2007) 59
3. Herman M., Weinstein T., Korzets A., et al. Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients. J Lab Clin Med 137 (2001) 14
4. Hojo M., Morimoto T., Maluccio M., et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397 (1999) 530
5. Koehl G., Andrassy J., Guba M., et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 77 (2004) 1319
6. Guba M., von Breitenbuch P., Steinbauer M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8 (2002) 128
7. McCarthy M. Antiangiogenesis drug promising for metastatic colorectal cancer. Lancet 361 (2003) 1959
8. Guba M., Yezhelyev M., Eichhorn M.E., et al. Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood 105 (2005) 4463
9. Bruns C.J., Koehl G., Guba M., et al. Rapamycin-induced endothelial cell death and tumor-vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clin Cancer Res 10 (2004) 2109
10. Weppler S.A., Krause M., Zyromska A., et al. Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: possible role for thrombosis. Radiother Oncol 82 (2007) 96
11. Lang S.A., Gaumann A., Koehl G.E., et al. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer 120 (2007) 1803
12. Thomas G.V., Tran C., Mellinghoff I.K., et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12 (2006) 122
13. Lee D.F., Kuo H.P., Chen C.T., et al. IKKb suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130 (2007) 440
14. Koehl G., Gaumann A., Zuelke C., et al. Development of de novo cancer in p53 knock-out mice is dependent on the type of long-term immunosuppression used. Transplantation 82 (2006) 741
15. Hernando E., Charytonowicz E., Dudas M.E., et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med 13 (2007) 748
16. Cautero N., De Luca S., Vecchi A., et al. Peritoneal leiomyosarcoma in a kidney transplant patient: a case report. Transplant Proc 39 (2007) 2038
17. Duncan F.J., Wulff B.C., Tober K.L., et al. Clinically relevant immunosuppressants influence UVB-induced tumor size through effects on inflammation and angiogenesis. Am J Transplant 7 (2007) 2693
18. O'Reilly K.E., Rojo F., She Q.B., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66 (2006) 1500
19. Harrington L.S., Findlay G.M., Gray A., et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 166 (2004) 213
20. Campistol J.M., Gutierrez-Dalmau A., and Torregrosa J.V. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 77 (2004) 760
21. Stallone G., Schena A., Infante B., et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352 (2005) 1317
22. Campistol J.M., Eris J., Oberbauer R., et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 17 (2006) 581
23. Kauffman H.M., Cherikh W.S., Cheng Y., et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80 (2005) 883